AlphAIalphai — Financial news for AI agents
investors.comSEP 42 min read$NVS

Novartis, Ionis Tumble On Surprise Flop For Heart Drug

Novartis (NVS) and Ionis (IONS) announced that their heart drug, pelacarsen, failed in Phase 3 trials. Both companies' stocks declined in after-hours trading. The drug targets Lp(a), a cardiovascular marker not significantly affected by diet or exercise.

Original reporting
investors.com
Published Sep 4, 2026, 10:15 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Sep 4, 2026, 10:30 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefTechnology
Primary signal
$NVS
Bearish
high confidence
Mentioned
$NVS · $IONS
Relevance
8/10
alphai data visualization · based on investors.com
Decision brief

The 30-second read

$NVSBearishHigh
01

Why it matters

Failure removes a high‑profile asset from both companies' pipelines, likely prompting re‑valuation of their cardiovascular franchises.

02

Market read

The announcement drives immediate negative sentiment for both stocks and may affect the broader biotech sector.

03

What to watch

Long‑term partnership terms may still provide future upside despite trial miss.

Relevance 8/10Novelty 9/10Timing: after‑hours Friday

Background

Pelacarsen was a late‑stage candidate aimed at reducing lipoprotein(a) to lower cardiovascular risk.

Company-level read

Ticker impact

$NVSBearishHigh confidence
Context

Novartis announced its Phase 3 failure of pelacarsen, causing a sharp after‑hours price drop.

Expected impact

down 5‑10% over next few days

Evidence & confidence

Phase 3 failure removes a key pipeline asset, reducing future revenue potential.

$IONSBearishHigh confidence
Context

Ionis Pharmaceuticals, partner on pelacarsen, saw its stock tumble after the Phase 3 miss.

Expected impact

down 4‑8% in the short term

Evidence & confidence

Loss of a major collaboration reduces expected royalty income.

Market effects

Sector

LPA‑lowering therapeutics sector faces setback, may pressure peers.

Regional

European biotech markets could see broader declines.

Global

Highlights risk in cardiovascular drug pipelines worldwide.

Counterpoint

What could challenge this read

Potential for a pivot to alternative indications or next‑generation LPA therapies.

Key entities

  • Company
    Novartis

    Swiss pharma giant developing pelacarsen.

  • Company
    Ionis Pharmaceuticals

    RNA‑targeted drug developer partnering on pelacarsen.

Read at source← All news

Related articles

SEP 4
$NVSMedAI 8/10

Novartis Pharma AG: Novartis announces Lp(a)HORIZON Phase III topline results for pelacarsen in patients with elevated Lp(a) and established cardiovascular disease (CVD)

Novartis announced that the Phase III Lp(a)HORIZON trial for pelacarsen did not meet its primary endpoint of reducing cardiovascular events. The study, involving 8,323 patients, showed that while pelacarsen lowered Lp(a) levels, it did not reduce cardiovascular risk. Novartis obtained rights to pelacarsen from Ionis Pharmaceuticals. Elevated Lp(a) affects about 20% of people worldwide and has no approved targeted treatment.

finanznachrichten.de2 min
SEP 4
$IONSHighAI 9/10

Weekly Buzz: IONS, MIST, BIIB, AZN Win Nods; TCRX, NVS Cut Jobs; OVID, VIR Data; REGN, PASG Deals

Ionis (IONS) and Milestone (MIST) gained FDA approvals for neurology and cardiology drugs. Biogen (BIIB) and AstraZeneca (AZN) also received regulatory nods for Alzheimer's and cancer treatments. Novavax (NVAX) secured global approvals for its COVID-19 vaccine. TScan (TCRX) and Novartis (NVS) announced job cuts. Novartis (NVS) and HUTCHMED (HCM) struck deals worth up to $3.2B and $1.295B respectively.

rttnews.com3 min
SEP 4
$IONSHighAI 9/10

IONS Secures FDA Nod for Rare Brain Disorder Drug Zanvastro

Ionis Pharmaceuticals (IONS) received FDA approval for Zanvastro, a treatment for Alexander disease, ahead of the expected date. The drug, backed by positive phase III study results, is the first disease-modifying treatment for this rare neurological condition. Ionis shares have fallen 27% year-to-date, and the company also received a rare pediatric disease priority review voucher, which could provide additional value.

yahoo.com3 min
SEP 4
$IONSHighAI 8/10

Ionis nets Zanvastro US approval in first for Alexander disease

Ionis Pharmaceuticals received FDA approval for Zanvastro (zilganersen), a therapy for Alexander disease. The drug showed efficacy in stabilizing walking speed in patients aged five and older. Ionis plans to launch Zanvastro in the US soon, with Recordati holding ex-US rights. The company has not yet disclosed the drug's price.

yahoo.com2 min
SEP 4
$NVSMedAI 8/10

Novartis halts CAR T therapy trials after patient deaths

Novartis halted clinical trials for its CAR T therapy rapcabtagene autoleucel after three patient deaths due to severe immune reactions. Bristol Myers Squibb also paused trials for its competitor product zola-cel, citing reversible inflammatory events. Both therapies target CD19, a protein linked to immune responses, but can cause severe immune reactions. Neither company has identified a cause.

bioxconomy.com2 min
SEP 4
$NVSMedAI 8/10

Novartis commits $3.2B to subcutaneous delivery

Novartis has secured exclusive rights to develop and commercialize subcutaneous versions of several products using Alteogen’s ALT-B4 technology. The deal could be worth up to $3.223 billion plus royalties if all options and milestones are met. This technology could potentially be used across multiple products, helping Novartis prepare for patent losses on major medicines. Alteogen has also signed similar deals with Biogen and GSK’s Tesaro. Novartis is also investing in other delivery technologie

european-biotechnology.com2 min